Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.39 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7993621 | 1.00 | OPRM1 (0.41) | OPRM1SIGMAR1FUCA1ACHECYP1A2 | |
| SCHEMBL7495999 | 0.75 | CHRM3 (0.39) | SIGMAR1FUCA1ACHECYP1A2CYP3A4 | |
| SCHEMBL9179426 | 0.73 | OPRM1 (0.46) | OPRM1SIGMAR1FUCA1 | |
| SCHEMBL7493871 | 0.72 | CYP2D6 (0.40) | OPRM1CYP2D6ALDH1A1 | |
| SCHEMBL8924879 | 0.71 | OPRM1 (0.41) | OPRM1SIGMAR1FUCA1 | |
| SCHEMBL7492595 | 0.70 | OPRL1 (0.38) | SIGMAR1ACHE | |
| SCHEMBL5534419 | 0.70 | FUCA1 (0.47) | SIGMAR1FUCA1ACHECYP1A2CYP3A4 | |
| SCHEMBL31459863 | 0.70 | FUCA1 (0.47) | SIGMAR1FUCA1ACHECYP1A2CYP3A4 | |
| SCHEMBL7496985 | 0.69 | OPRM1 (0.41) | OPRM1ACHE | |
| SCHEMBL20811430 | 0.69 | OPRM1 (0.36) | OPRM1SIGMAR1FUCA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0944385-B1 | USE OF 7-(1-AMINOMETHYL-2-OXA-7-AZA-BICYCLO 3.3.0]OCT-7-YL)-QUINOLONE CARBOXYLIC ACID AND NAPHTHYRIDONE CARBOXYLIC ACID DERIVATIVES FOR TREATING HELICOBACTER PYLORI INFECTIONS AND THE GASTRODUODENAL DISEASES ASSOCIATED THEREWITH | BAYER AG (DE) | 2002-10-16 | — | — | EP | disclosed |
| US-20010036941-A1 | Use of 7-(1-aminomethyl-2-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)-quinolonecarboxylic acid and -naphthyridonecarboxylic acid derivatives for the therapy of Helicobacter pylori infections and associated gastroduodenal disorders | PETERSEN UWE (DE) | 2001-11-01 | — | — | US | disclosed |
| US-6288081-B1 | Use of 7-(1-aminomethyl-2-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)-quinolone carboxylic acid and naphthyridone carboxylic acid derivatives for treating Helicobacter pylori infections and the gastroduodenal diseases associated therewith | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-11 | — | — | US | disclosed |
| EP-0944385-A2 | USE OF 7-(1-AMINOMETHYL-2-OXA-7-AZA-BICYCLO 3.3.0]OCT-7-YL)-QUINOLONE CARBOXYLIC ACID AND NAPHTHYRIDONE CARBOXYLIC ACID DERIVATIVES FOR TREATING $i(HELICOBACTER PYLORI) INFECTIONS AND THE GASTRODUODENAL DISEASES ASSOCIATED THEREWITH | BAYER AG (DE) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998026768-A2 | USE OF 7-(1-AMINOMETHYL-2-OXA-7-AZA-BICYCLO[3.3.0]OCT-7-YL)-QUINOLONE CARBOXYLIC ACID AND NAPHTHYRIDONE CARBOXYLIC ACID DERIVATIVES FOR TREATING HELICOBACTER PYLORI INFECTIONS AND THE GASTRODUODENAL DISEASES ASSOCIATED THEREWITH | BAYER AKTIENGESELLSCHAFT (DE) | 1998-06-25 | — | — | WO | disclosed |
| US-5621105-A | REACTING HALO-SUBSTITUTED QUINOLONECARBOXYLIC ACID OR NAPHTHYRIDONECARBOXYLIC ACID WITH 1-AMINOMETHYL-2-OXA-7-AZABICYCLO/3.3.0/OCTANE | BAYER AKTIENGESELLSCHAFT (DE) | 1997-04-15 | — | — | US | disclosed |
| US-5574161-A | GRAMPOSITIVE BACTERICIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1996-11-12 | — | — | US | disclosed |
| EP-0589318-B1 | Antibacterial 7-(aminomethyl-oxa-7-azabicyclo(3.3.0)oct-7-yl)quinolone- and -naphthyridonecarboxylic acid derivatives | BAYER AG (DE) | 1995-11-15 | — | — | EP | disclosed |
| US-5395944-A | Bactericides | BAYER AKTIENGESELLSCHAFT (DE) | 1995-03-07 | — | — | US | disclosed |
| EP-0589318-A2 | Antibacterial 7-(aminomethyl-oxa-7-azabicyclo(3.3.0)oct-7-yl)quinolone- and -naphthyridonecarboxylic acid derivatives | BAYER AG (DE) | 1994-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036941-A1 | Use of 7-(1-aminomethyl-2-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)-quinolonecarboxylic acid and -naphthyridonecarboxylic acid derivatives for the therapy of Helicobacter pylori infections and associated gastroduodenal disorders | OXER1, AOC3, PAM | OPRM1 499/4885SIGMAR1 436/4885FUCA1 4576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.